




VALUING A CURE: ARE NEW APPROACHES NEEDED?


Mark Sculpher, PhD

Professor of Health Economics Centre for Health Economics University of York, UK


Complexity in evaluation




Complexity in evaluation




Cost-effectiveness and affordability




Cost-effectiveness and affordability




Cost-effectiveness and affordability



Cost-effectiveness and affordability



Cost-effectiveness and affordability




Estimating opportunity cost by budget impact




Lomas et al. Value in Health, 2018, 21:266-275

Evidential uncertainty – example of oncology




Example in oncology



Othus et al. Value in Health 2017;20:705-9

Decision uncertainty and its implications



Dealing with uncertainty

Analysis

- · Magnitude and cost of uncertainty
- Key uncertainties
- · Feasibility & timing of research
- Irrecoverable costs
- Impact of price changes

Policy responses

- Fund
- Reject
- Price reduction
- Risk-sharing
- Fund only in research
- Fund with research

Should we value putative cures differently?

- Product A
- 2 life-years gained
- Good QoL
- Die of disease

Versus

- Product B
- 2 life-years gained
- Good QoL
- Die of other causes

Conclusions

- · Evaluation challenges not unique to 'cures'
- · The toolkit exists, needs to be used
- · Always need for further development
 - Survival modelling
 - Policy responses to uncertainty
 - Policy responses to high upfront costs

Thank you!

mark.sculpher@york.ac.uk



https://www.york.ac.uk/che/



@MJSculpher